## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

oplicants:

Baker et al.

Docket No:

39780-2830P1C48

Serial No:

10/015,389

Group Art Unit:

1647

Filed:

December 11, 2001

Examiner:

Rachel B. Kapust

For:

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

ACIDS ENCODING THE SAME

Commissioner for Patents Washington, D.C. 20231

Considered RBK 6/21/04

## DECLARATION OF LUC DESNOYERS, Ph.D. UNDER 37 CFR 1.131

I, Luc Desnoyers, Ph.D. declare and say as follows:

- I am scientist at the Molecular Oncology Department of Genentech, Inc., South San Francisco, CA 94080.
- 2. I am one of the inventors of the above-identified application.
- I have read and understood the claims pending in this application, and I am aware that
  the claims have been rejected as anticipated by International Patent Application
  Publication No. WO 00/00610 (Lal et al., publication date January 6, 2000).
- I, along with other inventors of this application, conceived and reduced to practice the invention claimed in the above-identified application in the United States prior to January 6, 2000.
- 5. At the time the present invention was made I was, as still am, responsible for overseeing the testing of novel polypeptides, including the polypeptide designated PRO1412, in chondrocyte proliferation assay (Assay #111, Example 153). This assay is used to find agents that are capable of inducing chondrocyte proliferation and/or redifferentiation, and can, therefore, be used in the treatment of joint diseases using a tissue engineering approach or as promising drug candidates to repair aging or arthritic joints, for example, in which the chondrocytes have been dedifferentiated.
- 6. In this assay, isolated chondrocyte cells are seeded in 96 well plates with either serum-free medium (no treatment control), or serum-free medium containing the test